CN112891391A - Application of Mongolian medicine leonurus alba extract in preparation of medicines for preventing and/or treating inflammatory diseases - Google Patents
Application of Mongolian medicine leonurus alba extract in preparation of medicines for preventing and/or treating inflammatory diseases Download PDFInfo
- Publication number
- CN112891391A CN112891391A CN202110225029.XA CN202110225029A CN112891391A CN 112891391 A CN112891391 A CN 112891391A CN 202110225029 A CN202110225029 A CN 202110225029A CN 112891391 A CN112891391 A CN 112891391A
- Authority
- CN
- China
- Prior art keywords
- extract
- herba leonuri
- inflammation
- mongolian medicine
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 102
- 239000000284 extract Substances 0.000 title claims abstract description 66
- 241000207925 Leonurus Species 0.000 title claims abstract description 13
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 title claims description 32
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title description 21
- 206010061218 Inflammation Diseases 0.000 claims abstract description 53
- 230000004054 inflammatory process Effects 0.000 claims abstract description 51
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 16
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 8
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 8
- 208000015181 infectious disease Diseases 0.000 claims abstract description 8
- 230000002458 infectious effect Effects 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000005325 percolation Methods 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 238000002803 maceration Methods 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 18
- 206010040047 Sepsis Diseases 0.000 abstract description 11
- 210000004698 lymphocyte Anatomy 0.000 abstract description 10
- 210000000440 neutrophil Anatomy 0.000 abstract description 9
- 210000000056 organ Anatomy 0.000 abstract description 9
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 8
- 230000006378 damage Effects 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 238000010172 mouse model Methods 0.000 abstract description 4
- 206010040872 skin infection Diseases 0.000 abstract description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 2
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 230000009885 systemic effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 23
- 239000003085 diluting agent Substances 0.000 description 17
- 210000004712 air sac Anatomy 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 14
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 230000008961 swelling Effects 0.000 description 13
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 235000010418 carrageenan Nutrition 0.000 description 10
- 239000000679 carrageenan Substances 0.000 description 10
- 229920001525 carrageenan Polymers 0.000 description 10
- 229940113118 carrageenan Drugs 0.000 description 10
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 10
- 102000003814 Interleukin-10 Human genes 0.000 description 9
- 108090000174 Interleukin-10 Proteins 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 210000002865 immune cell Anatomy 0.000 description 9
- 229940076144 interleukin-10 Drugs 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 210000005259 peripheral blood Anatomy 0.000 description 9
- 239000011886 peripheral blood Substances 0.000 description 9
- -1 polyoxyethylene Polymers 0.000 description 9
- 240000003271 Leonurus japonicus Species 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 210000003371 toe Anatomy 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 229940032147 starch Drugs 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241001092489 Potentilla Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 3
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 235000001046 cacaotero Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 241000007047 Panzerina lanata Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 108040006870 interleukin-10 receptor activity proteins Proteins 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QOPBEBWGSGFROG-UHFFFAOYSA-N 2-(1h-indol-2-yl)acetic acid Chemical class C1=CC=C2NC(CC(=O)O)=CC2=C1 QOPBEBWGSGFROG-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 244000141006 Armeniaca sibirica Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 1
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000010007 Xuebijing Substances 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000212 effect on lymphocytes Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005256 gram-negative cell Anatomy 0.000 description 1
- 230000033687 granuloma formation Effects 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003870 salicylic acids Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of a Mongolian medicine motherwort herb (herba leonuri) extract in preparing a medicine for treating and/or preventing inflammatory diseases. The Mongolian medicine herba leonuri (herba leonuri) extract has a reversing effect on pathological injuries of systemic inflammation (such as sepsis) and local inflammation (local skin infection and aseptic inflammation) of a plurality of inflammation model mice; can obviously inhibit the levels of inflammatory cytokines TNF-alpha, IL-6 and the like in blood and organs of a model mouse; remarkably inhibiting the total number of leucocytes, neutrophils and lymphocytes in blood and organs of a model mouse; has the function of obviously improving the infectious inflammation state of the organs of the model mouse such as eyes, intestinal tracts and the like.
Description
Technical Field
The invention belongs to the technical field of medicines or foods, and particularly relates to a Mongolian medicine herba leonuri (herba leonuri), a preparation method thereof, and application thereof in preparing medicines or foods for preventing and/or treating inflammatory diseases.
Background
Inflammation is the most basic anti-injury reaction of the body, and any factor which can cause tissue injury can be the cause of inflammation. The cause of inflammation is known as the inflammatory factor. Inflammatory factors are divided into biological factors such as bacteria, viruses, and metabolites thereof; physical factors such as extrusion, high temperature, low temperature, ultraviolet rays, etc.; chemical factors, including exogenous and endogenous chemicals; when the immune reaction state is abnormal, inappropriate or excessive immune reaction can be caused, so that tissue damage is caused, and inflammation, such as pollen allergy, autoimmunity and the like, is formed. According to the difference of the inflammatory disease duration, the inflammation is clinically divided into four types, namely hyperacute inflammation which has severe reaction and can cause serious tissue and organ damage and even cause death of the organism in a short period and is mostly seen in allergic inflammation; acute inflammation characterized by telangiectasia, increased permeability, extravasation, and edema; subacute inflammation characterized by platelet adhesion and leukocyte migration; chronic inflammation characterized by lymphocyte, macrophage infiltration, fibrous tissue proliferation, granuloma formation. The inflammatory reaction is a process in which multiple cytokines participate in the generation and development of inflammation by regulating the balance between proinflammatory and anti-inflammatory systems, and is a comprehensive pathological process integrating injury, injury resistance and repair. Inflammation can promote wound healing and resist invasion of foreign microorganisms, and can bring much harm to the body. At present, except for the obvious anti-inflammatory effect of glucocorticoid medicaments, the glucocorticoid medicaments have no real anti-inflammatory medicaments, the non-steroidal anti-inflammatory medicaments (NSAIDs) have limited anti-inflammatory effects, and salicylic acids, pyrazolones, indoleacetic acids and the like have the anti-inflammatory mechanism of inhibiting cyclooxygenase, which is a main reaction enzyme in the metabolism process of arachidonic acid, reducing prostaglandin synthesis and playing roles of relieving fever, easing pain and resisting inflammation. Such drugs do not have the effect of modulating inflammatory cells and inhibiting the production of inflammatory factors. And has reduced clinical use due to its severe hepatorenal and hematological toxicity.
In inflammatory diseases, infectious inflammatory diseases are complex, multiple immune cells are activated in an acute stage, an immune defense system is started, foreign invaders are phagocytized, a large number of inflammatory factors are released, and the inflammatory state at the stage effectively plays an antimicrobial role; however, a large amount of inflammatory factors can cause serious damage to the infected tissue, so once the foreign microorganisms are cleared, inflammation needs to be resolved in the middle and later stages to avoid damaging tissues and organs. Therefore, modulation of immune cells and inflammatory factors is key to anti-inflammation. To date, the search for safe and effective new drugs for treating inflammation is always a hot spot of research on anti-inflammatory and immunoregulatory drugs at home and abroad.
The acute inflammation of aseptic inflammation can be recovered by self without drug treatment, such as burn, scald, contusion and wound injury. Such inflammation is caused by increased vascular permeability, resulting in exudation of blood components, and increased production of prostaglandin, a pain-causing substance, resulting in pain, swelling, fever, and other discomfort symptoms in local tissues of wounds. The tissue repair can be accelerated by medicine intervention or physical treatment (cold and hot compress), and the discomfort of the organism can be relieved. Clinically, different therapeutic drugs are adopted for inflammation of different causes. The Chinese herbal medicine has good performances on infectious and aseptic inflammation, such as a lianhua antipyretic preparation, Xuebijing and the like which play good roles in preventing and treating new coronary pneumonia, and has a remarkable effect on treating mild patients. The multi-component and multi-target regulation mode of the traditional Chinese medicine is suggested to be used for resisting complex immune-inflammatory reaction or become a potential treatment medicine.
Herba Leonuri (Panzerina lanata) is a perennial herb of genus Potentilla of family Labiatae, and its variant. Is a unique Mongolian medicine. The pungent and bitter natures are recorded in the Chinese medicine dictionary Hai. Has effects in promoting blood circulation, dispelling blood stasis, removing toxic materials, and relieving swelling. The main treatment is as follows: menoxenia, puerperal abdominal pain, acute nephritis, acute mastitis, erysipelas, furuncle, scabies, etc. It is called as a crude drug for sore diseases in Shanxi and Neng Mongolia. At present, no relevant research report about the application of the extract and the effective part of the Mongolian medicine motherwort herb (pyocutaneous disease) in treating inflammation is found.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention provides the application of the extract of the Mongolian medicine motherwort herb in preparing anti-inflammatory drugs.
In order to solve the technical problem, the invention provides the following technical scheme:
an application of the extract of white motherwort herb in preparing the medicines for preventing and treating inflammation is disclosed.
The Mongolian medicine herba leonuri (pyocutaneous disease) extract is prepared by extracting the upper part of a pyogenic grassland serving as a raw material by using water or a C1-C5 lower alcohol aqueous solution as a solvent, and concentrating to obtain the Mongolian medicine herba leonuri (pyogenic disease) extract.
The extraction is carried out by any one of impregnation, percolation, decoction, heating reflux or ultrasound.
The volume concentration of the C1-C5 lower alcohol in the C1-C5 lower alcohol aqueous solution is 0-95%.
Preferably, the extraction solvent is a C1-C3 lower alcohol aqueous solution, and more preferably an ethanol aqueous solution;
the lower alcohol concentration is preferably 50 to 80% (v/v), more preferably 70 to 80% (v/v);
the inflammatory disease is inflammation of infectious system, local skin infection inflammation or aseptic inflammation.
1-2% of carrageenan induces foot swelling and air sac inflammation of mice, 1mg/kg of lipopolysaccharide induces sepsis, the Mongolian medicine herba leonuri (herba leonuri) extract is used for gastric perfusion administration at the crude drug dosage of 0.5-20 g/kg, and the toe swelling degree of the mice is reduced; reduce the exudation volume and turbidity of air sac liquid, and reduce the symptoms of inflammation of mice, such as eyes unclean, thin stool, hair dressing, lackluster, etc. Has regulating and controlling effect on neutrophil and lymphocyte in peripheral blood and air sac fluid of mouse.
A medicine for preventing and/or treating inflammation diseases contains the extract of herba Leonuri as the active component.
The medicine is an active ingredient and a pharmaceutically acceptable carrier or excipient, wherein the content of the active ingredient accounts for 0.1-99% of the mass of the medicine.
The Mongolian medicine herba leonuri (pyocutaneous disease) extract is prepared by extracting the upper part of a pyogenic grassland serving as a raw material by using water or a C1-C5 lower alcohol aqueous solution as a solvent, and concentrating to obtain the Mongolian medicine herba leonuri (pyogenic disease) extract.
If desired, the active ingredient may be combined with one or more solid or liquid pharmaceutical excipients and/or adjuvants and formulated into a suitable administration form or dosage form for human administration.
The pharmaceutical compositions of the present invention may be administered in unit dosage form, either enterally or parenterally, for example orally, intramuscularly, subcutaneously, nasally, oromucosally, dermally, peritoneally or rectally, and the like.
The route of administration of the pharmaceutical composition of the present invention may be administration by injection. The injection includes intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection, acupoint injection, etc. The administration dosage form can be liquid dosage form or solid dosage form. For example, the liquid dosage form can be true solution, colloid, microparticle, emulsion, or suspension. Other dosage forms such as tablet, capsule, dripping pill, aerosol, pill, powder, solution, suspension, emulsion, granule, suppository, lyophilized powder for injection, etc.
The composition can be prepared into common preparations, sustained release preparations, controlled release preparations, targeting preparations and various microparticle drug delivery systems.
In order to prepare the unit dosage form into tablets, various carriers well known in the art can be widely used. Examples of the carrier are, for example, diluents and absorbents such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate and the like; wetting agents and binders such as water, glycerin, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia slurry, gelatin slurry, sodium carboxymethylcellulose, shellac, methyl cellulose, potassium phosphate, polyvinylpyrrolidone and the like; disintegrating agents such as dried starch, alginates, agar powder, brown algae starch, sodium hydrogen carbonate and citric acid, calcium carbonate, polyoxyethylene sorbitol fatty acid esters, sodium dodecyl sulfate, methyl cellulose, ethyl cellulose, etc.; disintegration inhibitors such as sucrose, glyceryl tristearate, cacao butter, hydrogenated oil and the like; absorption accelerators such as quaternary ammonium salts, sodium lauryl sulfate and the like; lubricants, for example, talc, silica, corn starch, stearate, boric acid, liquid paraffin, polyethylene glycol, and the like. The tablets may be further formulated into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer and multi-layer tablets.
For making the administration units into pills, a wide variety of carriers well known in the art can be used. Examples of the carrier are, for example, diluents and absorbents such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, kaolin, talc and the like; binders such as acacia, tragacanth, gelatin, ethanol, honey, liquid sugar, rice paste or batter, etc.; disintegrating agents, such as agar powder, dried starch, alginate, sodium dodecylsulfate, methylcellulose, ethylcellulose, etc.
For making the administration unit into a suppository, various carriers well known in the art can be widely used. As examples of the carrier, there are, for example, polyethylene glycol, lecithin, cacao butter, higher alcohols, higher alcohol enzymes, gelatin, semisynthetic glycerase and the like.
To encapsulate the administration units, the active ingredient is mixed with the various carriers described above, and the mixture thus obtained is placed in hard gelatin capsules or soft gelatin capsules. Or making into microcapsule, suspending in aqueous medium to form suspension, or making into hard capsule or injection.
For example, the composition of the present invention is formulated into an injectable preparation, such as a solution, a suspension solution, an emulsion, a lyophilized powder, which may be aqueous or non-aqueous, and may contain one or more pharmaceutically acceptable carriers, diluents, binders, lubricants, preservatives, surfactants or dispersants. For example, the diluent may be selected from water, ethanol, polyethylene glycol, 1, 3-propanediol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitol fatty acid enzyme, etc. In addition, for the preparation of isotonic injection, sodium chloride, glucose or glycerol may be added in an appropriate amount to the preparation for injection, and conventional cosolvents, buffers, pH adjusters and the like may also be added. These adjuvants are commonly used in the art.
In addition, if desired, colorants, preservatives, flavors, flavorings, sweeteners, or other materials may also be added to the pharmaceutical preparation.
The dose of the pharmaceutical composition of the present invention to be administered depends on many factors, such as the nature and severity of the disease to be prevented or treated, the sex, age, body weight, character and individual response of the patient or animal, the administration route, the number of administrations, etc., and thus the therapeutic dose of the present invention can be widely varied. Generally, the dosage of the pharmaceutical ingredients of the present invention used is well known to those skilled in the art. The amount of the drug actually contained in the final formulation of the pharmaceutical composition of the present invention can be suitably adjusted to achieve the desired therapeutically effective amount thereof, thereby achieving the purpose of the present invention for treating inflammation. In general, the daily dose of the extract is 0.001mg/kg body weight to 500mg/kg body weight, preferably 3mg/kg body weight to 30mg/kg body weight, for a patient weighing about 75 kg. The above-mentioned dosage may be administered in a single dosage form or divided into several, e.g., two, three or four dosage forms, which is limited by the clinical experience of the administering physician and the dosage regimen.
The invention has the advantages that:
(1) the invention belongs to a traditional Chinese medicine preparation, which is prepared from a Mongolian medicine, namely a white motherwort herb (pyocutaneous disease) extract, and has pure natural components, low toxic and side effects, and administration dosage which is obviously lower than the maximum tolerated dose of a mouse; (2) the extract can effectively prevent and treat inflammation, and has reversing effect on pathological injury of systemic inflammation and local inflammation of mice of various inflammation models; can obviously inhibit the levels of inflammatory cytokines TNF-alpha, IL-6 and the like in blood and organs of a model mouse; remarkably inhibiting the total number of leucocytes, neutrophils and lymphocytes in blood and organs of a model mouse; the composition has the effect of remarkably improving infectious inflammation states of organs such as eyes, intestinal tracts and the like of a model mouse; (3) the preparation process is simple and easy for standardized production.
Drawings
Fig. 1 is a graph showing the effect of the extract of the Mongolian medicine leonurus japonicus (P. sibirica) on the level of IL-6 in the major organ tissues of a mouse sepsis model (Mean ± Sd, n ═ 6).
Fig. 2 is a graph showing the effect of the extract of the Mongolian medicine leonurus japonicus (P. pyogenes) on the IL-10 level in the intestinal tissue of a mouse sepsis model (Mean ± Sd, n ═ 6) according to the embodiment of the present invention.
FIG. 3 is a graph showing the protective effect of the Mongolian medicine motherwort herb on the skin infection of mice with drug-resistant Staphylococcus aureus.
Detailed Description
The present invention is further illustrated by the following examples, but the present invention is not limited to these examples.
Example 1: preparation of Mongolian medicine herba leonuri (herba leonuri) extract
Taking 1kg of dry Mongolian medicine herba Leonuri (herba Leonuri) Leonurus, adding 5L of 75% ethanol, heating and refluxing at 100 deg.C for 1.5 hr, and filtering while hot. The filter residue is treated again by the same method; mixing the filtrates, and recovering ethanol under reduced pressure to obtain 100g extract as herba Leonuri Baicalensis (herba Leonuri) extract I.
The Mongolian medicine herba Leonuri (Panzerina lanata) is herba Leonuri (Potentilla furcifera) and its variant belonging to family Labiatae, genus Potentilla.
Example 2: preparation of dosage forms
The preparation of the following preparation formulations is carried out according to the prior art, wherein the extract in the following preparation formulations is the extract I obtained in the above example, and the preparation formulations are specifically as follows:
and (3) capsule preparation: 100g of Mongolian medicine herba leonuri (pyocutaneous disease) extract, 147.5g of dextrin and 2.5g of magnesium stearate are added, the mixture is fully and uniformly mixed, 1000 granules are prepared according to a capsule preparation method, the capsules are filled in 250mg, each granule contains 100mg of Mongolian medicine herba leonuri (pyocutaneous disease) extract, and the total amount of the granules is not less than 50%.
And (3) tablet preparation: taking 100g of Mongolian medicine herba leonuri (herba leonuri), adding 100g of starch, 80g of dextrin and 15g of cane sugar, fully stirring and uniformly mixing, preparing into granules, drying at the temperature of below 60 ℃, adding a proper amount of magnesium stearate and talcum powder, uniformly mixing, pressing into 1000 tablets, and coating sugar coat or film coat to obtain the traditional Chinese medicine.
Granules: taking 100g of Mongolian medicine herba leonuri (pyocutaneous disease) extract, adding a proper amount of sucrose and dextrin, preparing into granules according to a granule preparation method, drying, and preparing into 1000 g.
Pharmacological experiments
Experimental example 1: mongolian medicine herba leonuri (herba leonuri) extract I has inhibiting effect on carrageenan-induced toe swelling of mice
The method comprises the following steps: 18-20g of SPF male ICR mice are randomly divided into a normal control group, a model control group, a positive control group (dexamethasone, 0.5mg/kg, and administration by intragastric administration) and a drug treatment group (the extract I of the pyogenic herbs obtained by the extraction is diluted by water to obtain a diluent, and then the diluent containing the extract I of the pyogenic herbs equivalent to 0.25g, the diluent containing the extract I of the pyogenic herbs equivalent to 0.5g and the diluent containing the extract I of the pyogenic herbs equivalent to 1g are intragastric administered for each kilogram of mice), and each group contains 6 mice. The animals of each group were administered the drug by gavage, and the blank control group was administered the same volume of purified water; after 1 hour, 20 μ L of 1% carrageenan was injected to the toes, and the blank control group was injected with the same amount of physiological saline; toe thickness and volume drained were measured at 2 hours, 4 hours and 8 hours post injection, respectively (see table 1). Swelling rate calculation formula: swelling rate ═ (thickness after swelling-before swelling)/before swelling x 100%.
Table 1 toe swelling rate (%) at different time points after drug treatment (Mean ± Sd, n ═ 6)
Remarking: # p < 0.05, compared to a blank control group; p < 0.05, compared to model control.
As can be seen from Table 1, the Mongolian medicine herba leonuri (herba leonuri), namely the extract, can reduce carrageenan-induced toe swelling of mice by 0.5g/kg of administration dose of the herba leonuri, can obviously reduce the toe swelling of the mice, and compared with a single carrageenan-stimulated group, the rates of toe swelling of the mice in 2 hours, 4 hours and 8 hours are reduced, which indicates that the herba leonuri can inhibit the activation of inflammation and can also promote the regression of the inflammation.
Experimental example 2: inhibition effect of extract of Mongolian medicine herba leonuri (herba leonuri) on carrageenan-induced mouse ballonflam inflammation
The method comprises the following steps: after an SPF male ICR mouse is anesthetized by intraperitoneal injection, 18-20g of 2% pentobarbital sodium 5mg/kg, 6mL of sterile air is injected subcutaneously into the back, and the injection is performed after 3 days, and the mice are randomly divided into a normal control group, a model control group, a positive control group (dexamethasone, 0.5mg/kg, intragastric administration) and a drug treatment group (the pyogenic extract I is diluted by water to obtain a diluent, and then the diluent containing the extract I equivalent to 0.25g of crude pyogenic drugs, the diluent containing the extract I equivalent to 0.5g of crude pyogenic drugs and the diluent containing the extract I equivalent to 1g of crude pyogenic drugs are intragastric administration per kilogram of the mice), and each group contains 6 mice. The animals of each group were administered the drug by gavage, and the blank control group was administered the same volume of purified water; 1 hour later, 1m L1% carrageenan was injected into the air sac, and the blank control group was injected with the same amount of physiological saline; peripheral blood was collected at 4 hours, 12 hours and 24 hours after injection, respectively, and the absolute values and the ratios of lymphocytes and neutrophils were analyzed by flow cytometry. Collecting the air sac liquid for 24 hours, and analyzing the number of granulocytes in the air sac.
Regulating and controlling effect of Mongolian medicine herba leonuri (herba leonuri) extract on peripheral blood immune cells of mouse air sac inflammation
Carrageenan acts as a inflammatory agent and can cause the aggregation of inflammatory cells within the air sac. Changes in local inflammatory cells in the body are reflected by changes in the number and proportion of immune cells in the peripheral blood. The experiment aims to investigate the influence of the extract of the Mongolian medicine leonurus japonicus (pyocutaneous disease) on the regulation and control of immune cells in the mouse air sac inflammation, and the result is shown in table 2.
Table 2 effect of the extract of the mongolian medicine leonurus japonicus (pustule) on the number and proportion of granulocytes and lymphocytes in the mouse model of air pocket inflammation (Mean ± Sd, n ═ 6)
Remarking: # p < 0.05, compared to a blank control group; p < 0.05, compared to model control group
As can be seen from Table 2, the Mongolian medicine herba leonuri (herba leonuri) extract can obviously inhibit the increase of peripheral blood neutrophils induced by carrageenan within 4 hours and 12 hours by intragastric administration to the air sac inflammation model mouse at the administration doses of 0.25g/kg, 0.50g/kg and 1g/kg, so that the proportion is reduced; the number of lymphocytes in 4 hours is obviously reduced, the influence on 12 hours and 24 hours is small, and the change of the lymphocyte ratio is mainly changed due to the change of the number of neutrophils.
② influence of extract of herba Leonuri (herba Leonuri) for treating mouse air sac inflammation model on total inflammatory cell count
Carrageenan induces the release of local histochemical chemokines within the balloon, recruiting inflammatory cells to the balloon tissues and releasing into the balloon fluid. The inflammation degree can be known by detecting the number of inflammatory cells in the air sac fluid. The results are shown in Table 3.
TABLE 3 influence of the extract of the Mongolian medicine Leonurus japonicus (P. pyogenes) on the total number of inflammatory cells in the air sac fluid of the mouse model of air sac inflammation (Mean + -Sd, n ═ 6)
Remarking: # p < 0.05, compared to a blank control group; p < 0.05, compared to model control group
As can be seen from Table 3, the Mongolian medicine herba Leonuri (herba Leonuri) extract at the dosage of 0.25g/kg, 0.5g/kg, and 1g/kg administered by intragastric administration to mice with air sac inflammation model can significantly reduce the total number of inflammatory cells in air sac fluid of mice.
Experimental example 3: protection effect of Mongolian medicine herba leonuri (herba leonuri) extract on Lipopolysaccharide (LPS) induced mouse sepsis model
The method comprises the following steps: 18-20g of SPF male ICR mice are randomly divided into a normal control group, a model control group, a positive control group (dexamethasone, 0.5mg/kg, and the drugs are administrated by intragastric administration) and a drug treatment group (the pyogenic extract I is diluted by water to obtain a diluent, and then the diluent containing the extract I equivalent to 0.25g of crude pyogenic drugs, the diluent containing the extract I equivalent to 0.5g of crude pyogenic drugs and the diluent containing the diluent equivalent to 1g of crude pyogenic extract I are intragastric administered according to the intragastric administration of each kilogram of mice), and each group contains 6 mice. The animals of each group were administered the drug by gavage, and the blank control group was administered the same volume of purified water; injecting 10mg/kg LPS into the abdominal cavity of the mouse after 1 hour, and injecting equivalent physiological saline into a blank control group; peripheral blood was collected at 4 hours, 12 hours and 24 hours after injection, respectively, and the absolute values and the ratios of neutrophils and lymphocytes were analyzed by a flow cytometer. Organs were collected for 24 hours and analyzed for inflammatory factor levels.
Regulating and controlling effect of Mongolian medicine leonurus albus (pyocutaneous disease) extract on lipopolysaccharide-induced mouse sepsis model peripheral blood immune cells
Lipopolysaccharide (LPS) is a component of gram-negative cell walls. The bacteria are released after dissolution and are composed of specific polysaccharide, core polysaccharide and lipid A. The toxic component is mainly lipid A. Lipid A can bind to LPS-binding protein in host body, and can mediate the binding of LPS to cell membrane receptor CD14 and TLR 4. After binding to cell membrane receptors, the direct effects of LPS are manifested by activation of phagocytes and activation of plasma proteins. Both are normal stress physiological activities that the body performs in response to infection and inflammation. These activities put the body into an inflammatory state. The experiment aims to investigate the influence of the extract of the Mongolian medicine leonurus japonicus (pyocutaneous disease) on phagocytes in a mouse sepsis model, and the result is shown in table 4.
Table 4 effect of the extract of the mongolian medicine leonurus japonicus (pyocutaneous disease) on the ratio of neutrophils in peripheral blood of the mouse sepsis model (Mean ± Sd, n ═ 6)
Remarking: # p < 0.05, # p < 0.01, compared to a blank control group; p < 0.05, p < 0.001, compared to model control group
As can be seen from Table 4, administration of the Mongolian medicine herba Leonuri (herba Leonuri) extract at doses of 0.25g/kg, 0.5g/kg, and 1g/kg by intragastric administration to sepsis model mice can cause neutrophilia, resulting in increase of the ratio of neutrophils to lymphocytes, which indicates that herba Leonuri extract has the effect of enhancing acute phase phagocytic cell ability.
② influence of Mongolian medicine herba leonuri (herba leonuri) extract on level of enteritis sex factor IL-6 and IL-10 of mouse sepsis model
Interleukin 6(IL-6) is one of the interleukins, and has pleiotropic effects, and its production levels are continuously dysregulated and closely related to the occurrence and development of various autoimmune and chronic inflammatory diseases. IL-6 is an important mediator of the acute phase response to fever and inflammation. Interleukin 10 (IL-10), also known as a cytokine synthesis inhibitor, is produced mainly by activated T cells, but also by other cells such as activated B cells, monocyte-macrophages, kupffer cells, keratinocytes, etc. IL-10 is a potent immunosuppressive factor with multidirectional biological activity, and IL-10 prevents not only cytokine production, but also expression of chemokines, costimulatory molecules (CD80, CD86, and MHC II). IL-10 binds to IL-10R α and IL-10R β, both of which are expressed in most immune cells, and thus IL-10 can modulate different innate and adaptive immune cells in different ways to avoid immune dysregulation. Such as the induction of Treg and Tr1 cells or the expression of autocrine inhibitors targeting macrophages and dendritic cells (see figures 1 and 2).
As shown in figure 1, the Mongolian medicine herba leonuri extract can reduce the IL-6 level of spleen, liver, lung, intestine and kidney of mice with sepsis, and is most obvious in intestinal tract. Meanwhile, as can be seen in fig. 2, the leonurus japonicus extract has no obvious effect on the level of IL-10 in the intestinal tract, which may be the dynamic change of the inflammatory factors, so the change of the inflammatory factors should be continuously and dynamically monitored. The Mongolian medicine herba leonuri can play an anti-inflammatory role by regulating immune cells and inflammatory factors by combining the change of the proportion of peripheral blood white cells.
Experimental example 4: protection effect of Mongolian medicine herba leonuri (herba leonuri) extract on mouse skin infection drug-resistant staphylococcus aureus
The method comprises the following steps: the SPF grade male ICR mice, 18-20g, were randomly divided into a normal control group, a model control group, and a drug treatment group (1 g/kg of pyogenic extracts), each group containing 6 mice. The animals of each group were surgically removed of skin of the same area at the back neck, coated with drug-resistant staphylococcus aureus, and administered with the drug by gavage daily for 9 days, while the blank control group was administered with purified water of the same volume. Wound surface diameter was measured with a vernier caliper every day, and wound surface area was calculated (see fig. 3).
As can be seen from FIG. 3, after the skin wound of a mouse is inoculated with the drug-resistant staphylococcus aureus, the wound can be obviously reduced on the 3 rd day after the Mongolian medicine leonurus is given, and the hair of the wound appears on the 4 th day, and compared with a group infected by the drug-resistant staphylococcus aureus, the wound is reduced on the 5 th day and the hair appears on the 6 th day. In the case of only the wound without infection, the skin healing rate was slightly faster than that of the blank control group by administering the Mongolian medicine, herba Leonuri. The bacterial infected group was overall faster than the uninfected group, presumably primarily because peptone in the bacterial culture accelerated wound healing. Therefore, the Mongolian medicine herba leonuri extract can obviously accelerate the healing of skin wound through anti-infection.
Claims (8)
1. An application of the extract of white motherwort herb in preparing the medicines for preventing and treating inflammation is disclosed.
2. The use of claim 1, wherein the extract of the Mongolian medicine herba Leonuri alba (pyocutaneous disease) is prepared by extracting the upper part of a pyogenic grassland with water or aqueous solution of C1-C5 lower alcohol as solvent, and concentrating to obtain the extract of the Mongolian medicine herba Leonuri (pyocutaneous disease).
3. The use of claim 1, wherein the extraction is performed by any one of maceration, percolation, decoction, heating reflux or sonication.
4. The use according to claim 1, wherein said aqueous solution of a C1-C5 lower alcohol has a concentration of 0-95% by volume of a C1-C5 lower alcohol.
5. Use according to claim 1, characterized in that the inflammatory disease is an inflammatory system, an infectious local skin inflammation or a sterile inflammation.
6. A medicament for preventing and/or treating inflammatory diseases, characterized in that: the active component of the medicine contains the extract of the Mongolian medicine motherwort.
7. The medicament according to claim 6, characterized in that the medicament is an active ingredient and a pharmaceutically acceptable carrier or excipient, wherein the content of the active ingredient is 0.1-99% by mass of the medicament.
8. The medicine as claimed in claim 6 or 7, wherein the extract of the Mongolian medicine herba Leonuri (herba Leonuri) is prepared by extracting the upper part of the herba Imperatae with water or aqueous solution of C1-C5 lower alcohol as solvent, and concentrating to obtain the extract of Mongolian medicine herba Leonuri (herba Leonuri).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110225029.XA CN112891391A (en) | 2021-03-01 | 2021-03-01 | Application of Mongolian medicine leonurus alba extract in preparation of medicines for preventing and/or treating inflammatory diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110225029.XA CN112891391A (en) | 2021-03-01 | 2021-03-01 | Application of Mongolian medicine leonurus alba extract in preparation of medicines for preventing and/or treating inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112891391A true CN112891391A (en) | 2021-06-04 |
Family
ID=76108162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110225029.XA Pending CN112891391A (en) | 2021-03-01 | 2021-03-01 | Application of Mongolian medicine leonurus alba extract in preparation of medicines for preventing and/or treating inflammatory diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112891391A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2372934C1 (en) * | 2008-10-03 | 2009-11-20 | Институт общей и экспериментальной биологии Сибирского отделения Российской Академии наук (ИОЭБ СО РАН) | Method for preparing antiinflammatory agent |
| CN102258510A (en) * | 2010-05-27 | 2011-11-30 | 复旦大学 | Applications of leonurine in preparing medicines for preventing inflammation-related diseases |
| CN106265622A (en) * | 2015-05-18 | 2017-01-04 | 复旦大学附属眼耳鼻喉科医院 | Leonurine purposes in preparing retina optic nerve protection medicine |
-
2021
- 2021-03-01 CN CN202110225029.XA patent/CN112891391A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2372934C1 (en) * | 2008-10-03 | 2009-11-20 | Институт общей и экспериментальной биологии Сибирского отделения Российской Академии наук (ИОЭБ СО РАН) | Method for preparing antiinflammatory agent |
| CN102258510A (en) * | 2010-05-27 | 2011-11-30 | 复旦大学 | Applications of leonurine in preparing medicines for preventing inflammation-related diseases |
| CN106265622A (en) * | 2015-05-18 | 2017-01-04 | 复旦大学附属眼耳鼻喉科医院 | Leonurine purposes in preparing retina optic nerve protection medicine |
Non-Patent Citations (4)
| Title |
|---|
| WANG, QING-HU，等: "Anti-inflammatory effect and high performance liquid chromatography (HPLC) analysis of the EtOAc extract from Panzeria alaschanica", 《AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY》 * |
| WANG, QING-HU，等: "Anti-inflammatory effect and isolation of phenylethanoid and acylated flavone glycosides from Panzeria alaschanica", 《ZEITSCHRIFT FUER NATURFORSCHUNG, B: A JOURNAL OF CHEMICAL SCIENCES》 * |
| 侯凤飞，等: "蒙药白益母草的化学成分研究", 《中国实验方剂学杂志》 * |
| 赵奇慧: "蒙药白益母草生物碱对血管平滑肌细胞表型的干预作用及机制研究", 《中国优秀硕士学位论文全文数据库-医药卫生科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101264122B (en) | Hypericum extract, its making method and medicinal composition and use for treating diabetes | |
| JP2009542634A (en) | Pharmaceutical composition for the prevention and treatment of inflammatory diseases comprising extract | |
| CN101417070B (en) | Medicine combination for treating coprostasis and preparation method thereof | |
| US9303006B2 (en) | Line leaf inula flower lactone A and methods for preparing and using the same for treating myocarditis | |
| CN107137450B (en) | Pharmaceutical composition and application thereof | |
| CN107753535B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and application thereof | |
| CN103127273B (en) | Compound medicament for treating chronic liver disease and preparation method thereof | |
| CN108403882A (en) | A kind of red sage root composition and preparation method thereof for treating coronary heart disease | |
| CN112891391A (en) | Application of Mongolian medicine leonurus alba extract in preparation of medicines for preventing and/or treating inflammatory diseases | |
| US9393277B2 (en) | Application of Albizzia chinensis extract in preparation of medicine for treatment of gastric ulcer | |
| KR20040060808A (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| CN1679639A (en) | Oral soft capsule of medicinal preparation from blood-activating Chinese medicine pseudo-ginseng and leech extract | |
| CN112076247B (en) | Application of perilla leaf extract in preparation of medicine for treating chronic obstructive pulmonary disease | |
| JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
| CN112076249B (en) | Application of perilla leaf extract in preparing medicament for treating inflammatory bowel disease | |
| CN112076248A (en) | Application of perilla leaf extract in preparation of medicine for preventing and/or treating asthma | |
| CN101766676B (en) | Extract of Albizia chinensis (Osbeck) Merr, preparation method, combination and purpose thereof | |
| CN108938779A (en) | Traditional Chinese medicine composition for treating conjunctivitis, preparation method and application thereof | |
| CN116211944B (en) | Traditional Chinese medicine composition, preparation and application thereof | |
| CN116211933B (en) | Anticoccidial traditional Chinese medicine composition and application thereof | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN113876834B (en) | Application of traditional Chinese medicine extract in preparation of traditional Chinese medicine product for resisting hyperplasia of mammary glands | |
| KR100352148B1 (en) | Compositions for angiogenesis and preventing and treating arthritis comprising β-sitosterol | |
| CN116262114A (en) | Benzyl o-hydroxybenzoate and pharmaceutical composition and application thereof | |
| CN115212252A (en) | Application of Va drug Nierone in preparation of drugs for treating cerebral infarction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |